Overview
Acute dermal toxicity testing under OECD Test Guideline 402 is a critical component of nonclinical safety evaluation, designed to determine the adverse effects of a single dermal exposure to a test substance. The study assesses both local and systemic toxicity following topical application and is often required by regulatory agencies such as the FDA, EMA, and EPA for pharmaceuticals, industrial chemicals, medical devices, cosmetics, and agrochemicals. This test is essential for hazard classification, labeling, and the establishment of safe handling and exposure guidelines.
Purpose and Regulatory Relevance
The OECD 402 guideline defines procedures for evaluating acute toxicity via the skin by determining the median lethal dose (LD₅₀), which is the dose required to cause death in 50% of the test animals. These results are necessary for classification and labeling under international frameworks including the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) and REACH. In the context of Investigational New Drug (IND) applications, the data are used to justify safety margins and establish preclinical risk assessments for formulations involving dermal exposure.
Study Design and Methodology
The test material is applied once to the shaved, intact skin of test animals, most commonly rats or rabbits. The application site is covered with a semi-occlusive dressing and the substance remains in contact with the skin for 24 hours. Following this exposure period, the covering is removed and the skin is gently washed. Animals are then observed for clinical signs of systemic toxicity, dermal irritation, changes in body weight, and mortality over a 14-day period. A full gross necropsy is conducted at the end of the study to identify any pathological changes in internal organs.
Dose levels are determined based on prior data or via a preliminary sighting study, and typical group sizes include five animals per sex per dose group. Studies are performed in compliance with Good Laboratory Practice (GLP), and all observations and pathological findings are carefully recorded to ensure reproducibility and regulatory acceptance.
Observational Parameters and Endpoints
Key parameters monitored during the study include general clinical signs (e.g., lethargy, tremors, respiration), dermal responses (e.g., erythema, edema, necrosis), body weight measurements, and survival. At necropsy, macroscopic examination of organs is performed, and additional histopathological analysis may be included if systemic effects are observed or suspected. The LD₅₀ is estimated using statistical methods, and any dose-response trends in toxicity are documented.
Optional extensions of this protocol include evaluation of toxicokinetics, assessment of systemic absorption through dermal layers, and integration with phototoxicity assays if relevant to the test article’s use.
Integration into IND-Enabling Toxicology Programs
Acute dermal toxicity studies are frequently included in IND-enabling toxicology programs when the investigational compound or its formulation is designed for topical delivery, or when there is a significant risk of skin exposure during clinical administration or manufacturing. These studies provide crucial safety information for early-phase clinical trials and support the development of appropriate dosing regimens and clinical monitoring strategies.
When paired with dermal irritation (OECD 404) and skin sensitization (OECD 406) studies, a comprehensive dermal safety profile can be established. This is particularly important for compounds intended for chronic dermal use or those with molecular weights or physicochemical properties that suggest potential for dermal absorption.
Compliance and Quality Assurance
All acute dermal toxicity studies are performed under strict GLP conditions using validated protocols and controlled laboratory environments. Our facility maintains full regulatory compliance, with quality assurance units overseeing study conduct, data integrity, and report generation. Each study includes detailed documentation suitable for submission to the FDA, EMA, or other international regulatory bodies.
Why Choose Our Toxicology IND Services
Our toxicology facility, operated by Altogen Labs, specializes in regulatory-compliant safety assessment studies that support both early-stage and late-stage development of drug candidates and chemical compounds. Altogen Labs offers extensive experience in conducting GLP-compliant acute dermal toxicity studies in alignment with OECD 402 guidelines, tailored to meet the specific requirements of your test article and therapeutic program. From protocol development and dose selection to full toxicology reporting and regulatory submission support, Altogen Labs delivers end-to-end service with scientific precision and regulatory accuracy. Our team of skilled toxicologists and study directors ensures that each study meets the highest standards for data integrity, reproducibility, and global regulatory acceptance.